Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPAS feasibility study in neovascular age-related macular degeneration with submacular haemorrhage
2012-004078-24Phase 4Completed
- Sponsor
- King's College London
- Start
- Jan 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tissue-plasminogen activator, ranibizumab and perflutren in exudative macular degeneration, sponsored by King's College London. Primary endpoint: Mean ETDRS visual acuity at 3 months. Started Jan 2013; status: completed.
02
Drugs
tissue-plasminogen activatorranibizumabperflutren
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2012-004078-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004078-24.